Shire Settlement With Barr Permits Generic Adderall XR Entry In 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Questions over whether the deal will pass FTC muster demonstrate how jittery industry is becoming following a criminal probe into a Sanofi/Bristol agreement.
You may also be interested in...
ADHD Market Snapshot: Changes Blow In With Adderall XR Generics
The first generic versions of Shire's market-leading attention deficit/hyperactivity disorder medication Adderall XR (amphetamine extended release) are expected to hit the market April 1. This will deliver a kick to the remaining branded drugs in the category - though not as swiftly as some might expect
ADHD Market Snapshot: Changes Blow In With Adderall XR Generics
The first generic versions of Shire's market-leading attention deficit/hyperactivity disorder medication Adderall XR (amphetamine extended release) are expected to hit the market April 1. This will deliver a kick to the remaining branded drugs in the category - though not as swiftly as some might expect
Shire Specialty Pharmaceuticals President Mike Cola: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Shire’s head of ADHD, renal and GI products talks about upcoming launches, a sales force reconfiguration and licensing and acquisitions.